CD4 and atherosclerosis: Intravenously administered anti-CD3 monoclonal antibodies, effective in treating autoimmune diabetes in mice [106] and humans [107], also improve atherosclerosis in mice [108] by regulating Teff immune responses and expanding CD4+CD25+ Tregs.